CompareMarketResearchRequest a sample
Home / Healthcare / CRISPR-Integrated Gene Editing Delivery Devices

Healthcare · Market report

CRISPR-Integrated Gene Editing Delivery Devices Market Size, Share and Forecast 2026-2036

The global CRISPR-integrated gene editing delivery devices market is worth USD 366 mn in 2026 and is forecast to reach USD 994 mn by 2036, growing at a 10.5% CAGR. United States is the largest country market and Cartridges, cuvettes and reagents is the largest by product segment.

USD 366 mnMarket size 2026
USD 994 mnForecast 2036
10.5%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global CRISPR-integrated gene editing delivery devices market is worth USD 366 mn in 2026 and is forecast to reach USD 994 mn by 2036, growing at a 10.5% CAGR. United States is the largest country market and Cartridges, cuvettes and reagents is the largest by product segment.

ScopeElectroporation instruments and consumables used to deliver CRISPR editors and other payloads into cells: benchtop and large-volume systems, cartridges, cuvettes and reagents for research and cell therapy manufacturing.
IndustryHealthcare
Value 2025USD 330 mn
Value 2026USD 366 mn
Value 2036USD 994 mn
CAGR 2026-203610.5%
Volume 20263,663 thousand runs
Volume 20369,942 thousand runs
Average price 2026USD 100 per run
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

CRISPR-Integrated Gene Editing Delivery Devices market size and forecast, 2026-2036

Exhibit 1The global CRISPR-integrated gene editing delivery devices market is forecast to grow from USD 366 mn in 2026 to USD 994 mn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 10.5%
CRISPR-Integrated Gene Editing Delivery Devices market value, 2025 to 2036Market value by year. 2025: USD 330 mn; 2026: USD 366 mn; 2027: USD 405 mn; 2028: USD 447 mn; 2029: USD 494 mn; 2030: USD 546 mn; 2031: USD 603 mn; 2032: USD 667 mn; 2033: USD 737 mn; 2034: USD 814 mn; 2035: USD 900 mn; 2036: USD 994 mn. Compound annual growth rate 2026 to 2036: 10.5%.2025366 mn2026603 mn2031994 mn203610.5% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 366 mn
2027USD 405 mn
2028USD 447 mn
2029USD 494 mn
2030USD 546 mn
2031USD 603 mn
2032USD 667 mn
2033USD 737 mn
2034USD 814 mn
2035USD 900 mn
2036USD 994 mn

CRISPR-Integrated Gene Editing Delivery Devices market segmentation

By product

Exhibit 2Cartridges, cuvettes and reagents is the largest segment by product, with 46.0% of 2026 revenueEstimated share of 2026 global revenue, by product
CRISPR-Integrated Gene Editing Delivery Devices market share by product, 2026Share of 2026 revenue by product. Cartridges, cuvettes and reagents: 46.0%; Benchtop electroporators: 30.0%; Large-volume flow electroporation: 24.0%.Cartridges, cuvettes and reagents46.0%Benchtop electroporators30.0%Large-volume flow electroporation24.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Benchtop electroporators30.0%22.1%USD 110 mn7.2%
Large-volume flow electroporation24.0%33.2%USD 88 mn14.1%
Cartridges, cuvettes and reagents46.0%44.7%USD 168 mn10.2%

By end use

Exhibit 3Cell therapy manufacturing adds the most revenue by end use, growing from USD 139 mn in 2026 to USD 528 mn by 2036Estimated revenue in USD by end use, 2026 and 2036 forecast
CRISPR-Integrated Gene Editing Delivery Devices market by end use, 2026 and 2036Revenue by end use in 2026 and 2036. Cell therapy manufacturing: USD 139 mn in 2026, USD 528 mn in 2036, change +279%; Academic and basic research: USD 147 mn in 2026, USD 270 mn in 2036, change +84%; Biopharma discovery: USD 81 mn in 2026, USD 196 mn in 2036, change +143%.20262036 forecastChangeCell therapy manufacturing+279%139 mn528 mnAcademic and basic research+84%147 mn270 mnBiopharma discovery+143%81 mn196 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Cell therapy manufacturing38.0%53.1%USD 139 mn14.3%
Academic and basic research40.0%27.2%USD 147 mn6.3%
Biopharma discovery22.0%19.7%USD 81 mn9.3%

By delivery method

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Electroporation systems38.0%34.0%USD 139 mn9.3%
Microfluidic devices20.0%22.0%USD 73 mn11.6%
Lipid nanoparticle formulators24.0%28.0%USD 88 mn12.2%
Viral vector systems18.0%16.0%USD 66 mn9.2%

By editing target

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Ex vivo cell editing46.0%44.0%USD 168 mn10.0%
In vivo editing34.0%36.0%USD 125 mn11.1%
Plant and microbial editing20.0%20.0%USD 73 mn10.5%

By scale

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Research scale46.0%38.0%USD 168 mn8.4%
Preclinical and process development32.0%34.0%USD 117 mn11.2%
Clinical manufacturing22.0%28.0%USD 81 mn13.2%

Top 25 countries for CRISPR-integrated gene editing delivery devices by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 91.0% of 2026 revenue and the 25 countries below together hold 98.3%.

Exhibit 4United States is the largest country market at USD 168 mn in 2026, and the three largest countries hold 65.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
CRISPR-Integrated Gene Editing Delivery Devices market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 168 mn, 46.0%; China: USD 44 mn, 12.0%; Germany: USD 26 mn, 7.0%; United Kingdom: USD 22 mn, 6.0%; Japan: USD 18 mn, 5.0%; South Korea: USD 15 mn, 4.0%; France: USD 11 mn, 3.0%; Switzerland: USD 11 mn, 3.0%; Canada: USD 11 mn, 3.0%; Netherlands: USD 7.3 mn, 2.0%.United States168 mn 46.0%China44 mn 12.0%Germany26 mn 7.0%United Kingdom22 mn 6.0%Japan18 mn 5.0%South Korea15 mn 4.0%France11 mn 3.0%Switzerland11 mn 3.0%Canada11 mn 3.0%Netherlands7.3 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 168 mn46.0%USD 454 mn10.4%
2ChinaUSD 44 mn12.0%USD 142 mn12.4%
3GermanyUSD 26 mn7.0%USD 64 mn9.5%
4United KingdomUSD 22 mn6.0%USD 57 mn9.9%
5JapanUSD 18 mn5.0%USD 43 mn8.8%
6South KoreaUSD 15 mn4.0%USD 44 mn11.6%
7FranceUSD 11 mn3.0%USD 27 mn9.3%
8SwitzerlandUSD 11 mn3.0%USD 28 mn9.7%
9CanadaUSD 11 mn3.0%USD 28 mn9.7%
10NetherlandsUSD 7.3 mn2.0%USD 19 mn9.9%
11AustraliaUSD 5.0 mn1.4%USD 13 mn10.2%
12BelgiumUSD 4.1 mn1.1%USD 11 mn10.1%
13SwedenUSD 3.3 mn0.9%USD 8.8 mn10.1%
14SingaporeUSD 2.8 mn0.8%USD 8.1 mn11.3%
15TaiwanUSD 2.2 mn0.6%USD 6.7 mn11.5%
16DenmarkUSD 1.8 mn0.5%USD 4.9 mn10.3%
17IsraelUSD 1.8 mn0.5%USD 4.7 mn10.0%
18SpainUSD 1.4 mn0.4%USD 3.6 mn10.2%
19ItalyUSD 1.0 mn0.3%USD 2.7 mn10.1%
20BrazilUSD 0.84 mn0.2%USD 2.5 mn11.4%
21AustriaUSD 0.70 mn0.2%USD 1.8 mn9.9%
22IrelandUSD 0.55 mn0.1%USD 1.5 mn10.5%
23RussiaUSD 0.55 mn0.1%USD 1.6 mn11.2%
24PolandUSD 0.48 mn0.1%USD 1.4 mn11.3%
25MexicoUSD 0.33 mn0.09%USD 0.99 mn11.7%
Rest of worldUSD 6.2 mn1.7%USD 17 mn10.5%
Exhibit 5United States and China account for 61% of the USD 628 mn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
CRISPR-Integrated Gene Editing Delivery Devices market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 366 mn. United States: +USD 286 mn; China: +USD 98 mn; Germany: +USD 38 mn; United Kingdom: +USD 35 mn; South Korea: +USD 29 mn; 20 other countries: +USD 131 mn; Rest of world: +USD 11 mn. Market value 2036: USD 994 mn.Market value 2026366 mnUnited States+286 mnChina+98 mnGermany+38 mnUnited Kingdom+35 mnSouth Korea+29 mn20 other countries+131 mnRest of world+11 mnMarket value 2036994 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Thermo Fisher Scientific
  • Lonza
  • Bio-Rad Laboratories

Group 2: Regional and specialist players

  • MaxCyte
  • Harvard Bioscience
  • Nepa Gene
  • Mirus Bio
  • Eppendorf

Group 3: Emerging and niche players

  • Celetrix
  • Avectas
  • Kytopen

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the CRISPR-integrated gene editing delivery devices market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.5% is calculated from the resulting values.

The market is divided by product, by end use, by delivery method, by editing target, by scale. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the CRISPR-integrated gene editing delivery devices market?

The global CRISPR-integrated gene editing delivery devices market is estimated at USD 330 mn in 2025 and USD 366 mn in 2026.

How fast will the CRISPR-integrated gene editing delivery devices market grow?

It is forecast to reach USD 994 mn by 2036, a compound annual growth rate of 10.5% from 2026, an increase of USD 628 mn.

Which country is the largest market for CRISPR-integrated gene editing delivery devices?

United States is the largest market by revenue at USD 168 mn in 2026, 46.0% of the global total. The three largest countries together hold 65.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 12.4% a year from 2026 to 2036.

Which CRISPR-integrated gene editing delivery devices segment is largest?

In the by product split, Cartridges, cuvettes and reagents is the largest segment with 46.0% of 2026 revenue.

Who are the leading CRISPR-integrated gene editing delivery devices companies?

Global leaders include Thermo Fisher Scientific, Lonza, Bio-Rad Laboratories.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← CRISPR and Cas Gene Cancer Survivorship Nutrition →

All Healthcare markets →

Request a sample